Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:ALOG's Cash-to-Debt is ranked higher than
98% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:ALOG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.31  Med: 36.87 Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
NAS:ALOG's Equity-to-Asset is ranked higher than
87% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. NAS:ALOG: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:ALOG' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.71  Med: 0.83 Max: 0.88
Current: 0.86
0.71
0.88
Interest Coverage No Debt
NAS:ALOG's Interest Coverage is ranked higher than
97% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. NAS:ALOG: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:ALOG' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 7
Altman Z-Score: 9.11
Beneish M-Score: -2.73
WACC vs ROIC
7.85%
6.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 6.77
NAS:ALOG's Operating Margin % is ranked higher than
59% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. NAS:ALOG: 6.77 )
Ranked among companies with meaningful Operating Margin % only.
NAS:ALOG' s Operating Margin % Range Over the Past 10 Years
Min: -1.06  Med: 5.38 Max: 8.24
Current: 6.77
-1.06
8.24
Net Margin % 4.58
NAS:ALOG's Net Margin % is ranked higher than
60% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. NAS:ALOG: 4.58 )
Ranked among companies with meaningful Net Margin % only.
NAS:ALOG' s Net Margin % Range Over the Past 10 Years
Min: 0.94  Med: 5.08 Max: 8.34
Current: 4.58
0.94
8.34
ROE % 4.48
NAS:ALOG's ROE % is ranked higher than
57% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. NAS:ALOG: 4.48 )
Ranked among companies with meaningful ROE % only.
NAS:ALOG' s ROE % Range Over the Past 10 Years
Min: 0.9  Med: 5 Max: 9.9
Current: 4.48
0.9
9.9
ROA % 3.74
NAS:ALOG's ROA % is ranked higher than
63% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. NAS:ALOG: 3.74 )
Ranked among companies with meaningful ROA % only.
NAS:ALOG' s ROA % Range Over the Past 10 Years
Min: 0.76  Med: 4.19 Max: 7.98
Current: 3.74
0.76
7.98
ROC (Joel Greenblatt) % 12.23
NAS:ALOG's ROC (Joel Greenblatt) % is ranked higher than
57% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. NAS:ALOG: 12.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:ALOG' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2.21  Med: 11.09 Max: 18.74
Current: 12.23
-2.21
18.74
3-Year Revenue Growth Rate -2.70
NAS:ALOG's 3-Year Revenue Growth Rate is ranked lower than
71% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NAS:ALOG: -2.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:ALOG' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -10.4  Med: 7.2 Max: 15.9
Current: -2.7
-10.4
15.9
3-Year EBITDA Growth Rate -8.50
NAS:ALOG's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. NAS:ALOG: -8.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:ALOG' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.1  Med: 4.5 Max: 62.7
Current: -8.5
-41.1
62.7
3-Year EPS without NRI Growth Rate -27.10
NAS:ALOG's 3-Year EPS without NRI Growth Rate is ranked lower than
77% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. NAS:ALOG: -27.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:ALOG' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56  Med: 4.4 Max: 135.1
Current: -27.1
-56
135.1
GuruFocus has detected 1 Warning Sign with Analogic Corp $NAS:ALOG.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:ALOG's 10-Y Financials

Financials (Next Earnings Date: 2017-06-06 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ALOG Guru Trades in Q1 2016

Joel Greenblatt 35,680 sh (New)
NWQ Managers 544,777 sh (+7.09%)
Chuck Royce 565,701 sh (+4.23%)
Mariko Gordon 578,814 sh (+3.75%)
Jim Simons 19,800 sh (-8.98%)
Richard Snow 139,590 sh (-24.46%)
» More
Q2 2016

ALOG Guru Trades in Q2 2016

Joel Greenblatt 92,284 sh (+158.64%)
Chuck Royce 580,101 sh (+2.55%)
NWQ Managers 547,037 sh (+0.41%)
Jim Simons Sold Out
Mariko Gordon 567,408 sh (-1.97%)
Richard Snow 128,985 sh (-7.60%)
» More
Q3 2016

ALOG Guru Trades in Q3 2016

Chuck Royce 588,851 sh (+1.51%)
NWQ Managers 517,550 sh (-5.39%)
Richard Snow 97,775 sh (-24.20%)
Mariko Gordon 416,175 sh (-26.65%)
Joel Greenblatt 55,449 sh (-39.91%)
» More
Q4 2016

ALOG Guru Trades in Q4 2016

Chuck Royce 587,384 sh (-0.25%)
NWQ Managers 507,905 sh (-1.86%)
Mariko Gordon 275,769 sh (-33.74%)
Richard Snow 40,558 sh (-58.52%)
Joel Greenblatt 6,227 sh (-88.77%)
» More
» Details

Insider Trades

Latest Guru Trades with ALOG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 8071
Compare:NAS:BEAT, NAS:KANG, NAS:QDEL, NAS:HSKA, NAS:GHDX, NAS:ABAX, NAS:NEO, NAS:FMI, NAS:NRCIA, OTCPK:EPLYF, NAS:MYGN, NAS:VIVO, NAS:MEDP, NYSE:ARA, NAS:AXDX, NAS:PACB, NAS:VREX, NAS:NTRA, NYSE:NVTA, NAS:LNTH » details
Traded in other countries:AJM.Germany,
Headquarter Location:USA
Analogic Corp is a technology company that designs and manufactures medical imaging ultrasound and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users in the healthcare and airport security markets.

Analogic Corporation was incorporated in the Commonwealth of Massachusetts in November 1967. The company is a technology company that designs and manufactures medical imaging and security systems and subsystems sold to original equipment manufacturers, or OEMs, and end users mainly in the healthcare and airport security markets. The Company's operating segments are Ultrasound, Medical Imaging, and Security and Detection. The Ultrasound segment provides ultrasound guidance systems for the urology and surgery markets and is expanding into point of care areas such as anesthesia and emergency medicine. The Medical Imaging segment provides critical enabling medical imaging systems and subsystems for computed tomography, or CT, magnetic resonance imaging, or MRI and high-resolution digital mammography systems. The Security and Detection segment designs and manufactures automated threat detection systems for aviation baggage inspection applications utilizing CT technology. Its geographical areas include United states, Japan, Germany, Netherlands and others.

Top Ranked Articles about Analogic Corp

Analogic to Present at the 42nd Annual Deutsche Bank Health Care Conference
BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017

First Fully Integrated MR-to-Ultrasound Fusion Prostate Biopsy Solution

PEABODY, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (NASDAQ:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will introduce bkFusion, a groundbreaking solution for improving biopsy targeting in prostate cancer, at the 32nd Annual EAU (European Association of Urology) Congress, March 24–27 in London. bkFusion is the latest innovation from the company’s flagship BK Ultrasound brand. It is the first MR-fusion prostate biopsy application that is fully integrated onto a premium ultrasound system—the bk3000—for use by urologists in both hospital and office settings. The bk3000 system is designed for urology, general imaging and procedure guidance applications. Systematic biopsies don’t always give enough information to be conclusive. bkFusion seamlessly overlays MR image information about lesion location and extent onto real-time ultrasound images, without the need for an additional workstation. This improves workflow and minimizes the system’s footprint, which are significant benefits for the urologist performing biopsies in the office, enabling faster and more reliable disease management. BK Ultrasound, powered by Analogic, has partnered with MIM Software Inc. to create bkFusion. MIM is a provider of market-leading imaging solutions for radiation oncology, radiology, nuclear medicine, neuroimaging and cardiac imaging. This innovative software builds on MIM’s unique Predictive Fusion technology to enable the urologist to precisely biopsy MR-defined targets quickly and accurately. With its small footprint, the bk3000 fits easily into any office space and, because bkFusion is completely integrated on the ultrasound system, no additional bulky equipment or set-up time is required. The bkFusion system communicates easily with radiology departments, accessing the MR images via PACS or a secure cloud platform. “We are very pleased to launch bkFusion in partnership with MIM,” said Fred Parks, president and CEO. “This is the solution that our customers in the urology community have been looking for, made possible by combining MIM’s expertise in medical image processing for cancer visualization with our strength in specialty ultrasound. Unlike current solutions for MR-fusion, real-time ultrasound, rather than MR, is at the center of the workflow. The MR information helps to guide urologists more accurately to their target, and the prostate image quality provided by the bk3000 helps urologists visualize and revalidate subtle lesions.” “We are excited to partner with BK Ultrasound to bring this innovative application to urology,” said, Jon Piper, VP of R&D from MIM. “bkFusion makes it possible to harness the power of MR imaging in the urology office, providing patients with the clinical benefits of a more targeted biopsy in the privacy and comfort of their physician’s practice setting. Our approach has always been to focus on technology that benefits the greatest number of patients possible by being practical for use in centers of any size.” About Analogic – Celebrating 50 Years of innovation
Analogic (NASDAQ:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com. Analogic and the globe logo are registered trademarks, and BK Ultrasound, bkFusion and bk3000 are trademarks, of Analogic Corporation or its affiliated companies. Predictive Fusion is a trademark of MIM Software Inc.
Investor and Media Contact:
Mark Namaroff
Director of Investor Relations
(978) 326-4058
[email protected]

Read more...
Analogic to Present at the 16th Annual Needham Healthcare Conference

PEABODY, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (NASDAQ:ALOG), enabling the world’s medical imaging and aviation security technology, today announced that Mark Frost, senior vice president, chief financial officer and treasurer, will be presenting at the 16th Annual Needham Healthcare Conference at the Westin New York Grand Central Hotel in New York, New York, on Wednesday, April 5, 2017.
The 40-minute presentation, which includes a Q&A session, is scheduled to begin at 4:20 p.m. ET and will be webcast live. To view the webcast, visit investor.analogic.com About Analogic – Celebrating 50 Years of innovation
Analogic (NASDAQ:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com. Analogic and the globe logo are registered trademarks of Analogic Corporation.
For Further Information, Contact:
           
Investor Contact:
Mark Namaroff
Director of Investor Relations
(978) 326-4058
[email protected]

Read more...
Analogic to Launch Breakthrough Checkpoint Security Screening System for European Aviation Market at Passenger Terminal Expo 2017 in Amsterdam

New ConneCT Incorporates Latest Imaging Innovations for Lower Airport Costs, Faster Throughput and Improved Security

PEABODY, Mass., March 08, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (NASDAQ:ALOG), enabling the world's medical imaging and aviation security technology, today announced that it will launch its ConneCT™ Checkpoint CT (computed tomography) screening system for the European market at the Passenger Terminal Expo in Amsterdam, March 14–16. Utilizing Analogic’s advanced CT technology alongside state-of-the-art threat detection software, the ConneCT incorporates the latest in security and medical innovations to lower airport screening costs, increase passenger throughput and elevate the level of security for the traveling public.
Analogic’s ConneCT is the culmination of 25 years of leadership in advanced CT security screening solutions.  Analogic CT technology has been deployed at over 1,200 airports worldwide for checked baggage. The ConneCT checkpoint security system features a new modular imaging system based on advanced medical imaging technology and an interoperable network architecture designed to maximize reliability and achieve the lowest total cost of ownership. Its threat detection software is engineered to allow passengers to keep liquids and electronics in their carry-on baggage, increase staff productivity and reduce false alarms. “The launch of ConneCT is not only about Analogic’s leadership in CT technology – it also reflects a new direct partnership with technology decision-makers that gives airports more flexibility and lowers costs,” said Jim Ryan, senior vice president of security systems. “Our customers want direct access to the latest in screening technologies and the freedom to make ‘best-of-breed’ choices for complementary checkpoint equipment and software, as well as on-site service support. Analogic will enable dynamic and tailored solutions that evolve with airport needs over the lifecycle of the product.” “European airports have been early adopters of new technology, recognizing the opportunity to do three key things: improve detection capabilities to keep the traveling public safe, transform the airport experience for the traveling public and get passengers through security quickly so they can enjoy airport shopping and dining venues,” said Mark Laustra, vice president global business development and government relations. “We are pleased to launch ConneCT, our next-generation CT checkpoint scanner.” Analogic developed CT technology for medical use, adapting the technology for detection and security of checked baggage. The ConneCT has been engineered and designed specifically for airport checkpoints, representing a new industry standard for imaging, with 100x more data available in each image than the previous standard. This allows screeners to manipulate a 3D image to view bags from all angles, revealing items that might otherwise be hidden. In February of 2016, Neil Thompson, operations director of London Luton Airport, commented on Analogic’s UK trial of COBRA, Analogic’s first-generation checkpoint CT. "Through the trials with Analogic, we have been able to demonstrate ways to significantly improve security checks. Analogic 3D CT technology has shown the promise of providing a great passenger experience whilst improving security." Analogic will feature the ConneCT scanner at its booth (RAI Amsterdam, Hall 8, Booth #10050) during the Passenger Terminal Expo 2017 next week. On March 16, at 12:55 local time, Mark Laustra will deliver a presentation on the future of aviation security technology and regulation. The ConneCT screening system has achieved critical milestones on its way toward Transportation Security Administration (TSA) certification in the US and is slated to enter the ECAC certification protocol in the spring of this year. Analogic remains committed to working closely with various international certification agencies and airports this year to bring the ConneCT system to the global market. About Analogic – Celebrating 50 Years of innovation
Analogic (NASDAQ:ALOG) provides leading-edge healthcare and security technology solutions to advance the practice of medicine and save lives. We are recognized around the world for advanced imaging and real-time guidance technologies used for disease diagnosis and treatment as well as for automated threat detection. Our market-leading ultrasound systems, led by our flagship BK Ultrasound brand, used in procedure-driven markets such as urology, surgery, and point-of-care, are sold to clinical practitioners around the world. Our advanced imaging technologies are also used in computed tomography (CT), magnetic resonance imaging (MRI) and digital mammography systems, as well as automated threat detection systems for aviation security. Analogic is headquartered just north of Boston, Massachusetts. For more information, visit www.analogic.com. Analogic and the globe logo are registered trademarks of Analogic Corporation or its affiliated companies.
For further information, please contact:
     
Investor Contact:                                                            
Mark Namaroff                                                                
Director of Investor Relations                                           
(978) 326-4058                                                                
[email protected]

Media Contact:
Jennifer Webb
Coltrin & Associates, Inc.
(212) 221-1616
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 39.20
ALOG's PE Ratio is ranked lower than
66% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. ALOG: 39.20 )
Ranked among companies with meaningful PE Ratio only.
ALOG' s PE Ratio Range Over the Past 10 Years
Min: 16.49  Med: 33.45 Max: 148.85
Current: 39.2
16.49
148.85
PE Ratio without NRI 39.20
ALOG's PE Ratio without NRI is ranked lower than
64% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. ALOG: 39.20 )
Ranked among companies with meaningful PE Ratio without NRI only.
ALOG' s PE Ratio without NRI Range Over the Past 10 Years
Min: 17.99  Med: 34.39 Max: 178.18
Current: 39.2
17.99
178.18
Price-to-Owner-Earnings 40.33
ALOG's Price-to-Owner-Earnings is ranked lower than
70% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. ALOG: 40.33 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ALOG' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.84  Med: 54.24 Max: 839.04
Current: 40.33
12.84
839.04
PB Ratio 1.72
ALOG's PB Ratio is ranked higher than
83% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. ALOG: 1.72 )
Ranked among companies with meaningful PB Ratio only.
ALOG' s PB Ratio Range Over the Past 10 Years
Min: 0.82  Med: 1.83 Max: 2.53
Current: 1.72
0.82
2.53
PS Ratio 1.81
ALOG's PS Ratio is ranked higher than
75% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. ALOG: 1.81 )
Ranked among companies with meaningful PS Ratio only.
ALOG' s PS Ratio Range Over the Past 10 Years
Min: 0.78  Med: 1.8 Max: 3.09
Current: 1.81
0.78
3.09
Price-to-Free-Cash-Flow 22.93
ALOG's Price-to-Free-Cash-Flow is ranked lower than
52% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. ALOG: 22.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ALOG' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.87  Med: 33.17 Max: 169.1
Current: 22.93
13.87
169.1
Price-to-Operating-Cash-Flow 16.94
ALOG's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. ALOG: 16.94 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ALOG' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.02  Med: 21.42 Max: 81.55
Current: 16.94
9.02
81.55
EV-to-EBIT 23.56
ALOG's EV-to-EBIT is ranked higher than
50% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. ALOG: 23.56 )
Ranked among companies with meaningful EV-to-EBIT only.
ALOG' s EV-to-EBIT Range Over the Past 10 Years
Min: -121.6  Med: 24.6 Max: 388.6
Current: 23.56
-121.6
388.6
EV-to-EBITDA 13.87
ALOG's EV-to-EBITDA is ranked higher than
68% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. ALOG: 13.87 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALOG' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.9  Med: 15.1 Max: 48.4
Current: 13.87
5.9
48.4
PEG Ratio 11.15
ALOG's PEG Ratio is ranked lower than
88% of the 43 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.96 vs. ALOG: 11.15 )
Ranked among companies with meaningful PEG Ratio only.
ALOG' s PEG Ratio Range Over the Past 10 Years
Min: 0.79  Med: 2.89 Max: 356.36
Current: 11.15
0.79
356.36
Shiller PE Ratio 35.50
ALOG's Shiller PE Ratio is ranked higher than
57% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. ALOG: 35.50 )
Ranked among companies with meaningful Shiller PE Ratio only.
ALOG' s Shiller PE Ratio Range Over the Past 10 Years
Min: 15.53  Med: 35.54 Max: 53.68
Current: 35.5
15.53
53.68
Current Ratio 5.65
ALOG's Current Ratio is ranked higher than
80% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. ALOG: 5.65 )
Ranked among companies with meaningful Current Ratio only.
ALOG' s Current Ratio Range Over the Past 10 Years
Min: 2.82  Med: 5.96 Max: 9.1
Current: 5.65
2.82
9.1
Quick Ratio 3.63
ALOG's Quick Ratio is ranked higher than
70% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. ALOG: 3.63 )
Ranked among companies with meaningful Quick Ratio only.
ALOG' s Quick Ratio Range Over the Past 10 Years
Min: 2.13  Med: 4.47 Max: 6.87
Current: 3.63
2.13
6.87
Days Inventory 185.07
ALOG's Days Inventory is ranked lower than
85% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. ALOG: 185.07 )
Ranked among companies with meaningful Days Inventory only.
ALOG' s Days Inventory Range Over the Past 10 Years
Min: 92.53  Med: 118.65 Max: 185.07
Current: 185.07
92.53
185.07
Days Sales Outstanding 64.45
ALOG's Days Sales Outstanding is ranked lower than
52% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. ALOG: 64.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALOG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.76  Med: 68.08 Max: 80.63
Current: 64.45
58.76
80.63
Days Payable 37.71
ALOG's Days Payable is ranked lower than
63% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. ALOG: 37.71 )
Ranked among companies with meaningful Days Payable only.
ALOG' s Days Payable Range Over the Past 10 Years
Min: 29.72  Med: 36.48 Max: 45.64
Current: 37.71
29.72
45.64

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.55
ALOG's Dividend Yield % is ranked lower than
78% of the 101 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.97 vs. ALOG: 0.55 )
Ranked among companies with meaningful Dividend Yield % only.
ALOG' s Dividend Yield % Range Over the Past 10 Years
Min: 0.41  Med: 0.61 Max: 1.6
Current: 0.55
0.41
1.6
Dividend Payout Ratio 0.21
ALOG's Dividend Payout Ratio is ranked higher than
67% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.24 vs. ALOG: 0.21 )
Ranked among companies with meaningful Dividend Payout Ratio only.
ALOG' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.12  Med: 0.26 Max: 1.38
Current: 0.21
0.12
1.38
Forward Dividend Yield % 0.55
ALOG's Forward Dividend Yield % is ranked lower than
84% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.15 vs. ALOG: 0.55 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.54
ALOG's 5-Year Yield-on-Cost % is ranked lower than
84% of the 106 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.33 vs. ALOG: 0.54 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
ALOG' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.41  Med: 0.61 Max: 1.6
Current: 0.54
0.41
1.6
3-Year Average Share Buyback Ratio -0.40
ALOG's 3-Year Average Share Buyback Ratio is ranked higher than
77% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. ALOG: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALOG' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: 0.5 Max: 7.9
Current: -0.4
-1.6
7.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 13.78
ALOG's Price-to-Net-Cash is ranked lower than
60% of the 72 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 11.15 vs. ALOG: 13.78 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ALOG' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 3.17  Med: 8.26 Max: 148.14
Current: 13.78
3.17
148.14
Price-to-Net-Current-Asset-Value 2.92
ALOG's Price-to-Net-Current-Asset-Value is ranked higher than
84% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. ALOG: 2.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ALOG' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.05  Med: 2.4 Max: 4.77
Current: 2.92
1.05
4.77
Price-to-Tangible-Book 2.10
ALOG's Price-to-Tangible-Book is ranked higher than
81% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. ALOG: 2.10 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ALOG' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 1.76 Max: 3.17
Current: 2.1
0.76
3.17
Price-to-Intrinsic-Value-Projected-FCF 1.28
ALOG's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
71% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. ALOG: 1.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ALOG' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.61  Med: 1.3 Max: 2.06
Current: 1.28
0.61
2.06
Price-to-Intrinsic-Value-DCF (Earnings Based) 1.90
ALOG's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
59% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. ALOG: 1.90 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.00
ALOG's Price-to-Median-PS-Value is ranked lower than
51% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ALOG: 1.00 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ALOG' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.43  Med: 0.89 Max: 1.51
Current: 1
0.43
1.51
Price-to-Graham-Number 1.91
ALOG's Price-to-Graham-Number is ranked higher than
69% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. ALOG: 1.91 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ALOG' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.58  Med: 1.47 Max: 11.2
Current: 1.91
0.58
11.2
Earnings Yield (Greenblatt) % 4.23
ALOG's Earnings Yield (Greenblatt) % is ranked higher than
70% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. ALOG: 4.23 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ALOG' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 4 Max: 8.3
Current: 4.23
0.3
8.3
Forward Rate of Return (Yacktman) % 3.74
ALOG's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. ALOG: 3.74 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ALOG' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -20.7  Med: 6.2 Max: 33.9
Current: 3.74
-20.7
33.9

More Statistics

Revenue (TTM) (Mil) $518.7
EPS (TTM) $ 1.88
Beta0.94
Short Percentage of Float6.45%
52-Week Range $69.65 - 95.85
Shares Outstanding (Mil)12.49

Analyst Estimate

Jul17 Jul18
Revenue (Mil $) 533 575
EPS ($) 4.01 4.65
EPS without NRI ($) 4.01 4.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ALOG

Headlines

Articles On GuruFocus.com
Analogic to Present at the 42nd Annual Deutsche Bank Health Care Conference Apr 18 2017 
BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017 Mar 23 2017 
Analogic to Present at the 16th Annual Needham Healthcare Conference Mar 23 2017 
Analogic to Launch Breakthrough Checkpoint Security Screening System for European Aviation Market at Mar 08 2017 
Mariko Gordon Sells Stake in Dealertrack Technologies Dec 02 2015 
Mariko Gordon Uses Her Magic Touch and Acquires Holdings in Two Companies Nov 23 2015 
AMD Embedded Radeon(TM) HD 7850 GPU Accelerates Medical Imaging Jan 12 2015 
Could These Science Stocks Provide Big Gains? Mar 11 2012 
Weekly Top Insider Buys: Health Care REIT Inc., Human Genome Sciences Inc., Conseco Inc., Universal Jan 02 2010 
Analogic Corp. Reports Operating Results (10-K) Sep 29 2009 

More From Other Websites
ETFs with exposure to Analogic Corp. : April 19, 2017 Apr 19 2017
Analogic to Present at the 42nd Annual Deutsche Bank Health Care Conference Apr 18 2017
Analogic to Present at the 16th Annual Needham Healthcare Conference Mar 23 2017
BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017 Mar 23 2017
Analogic Corp. :ALOG-US: Earnings Analysis: Q2, 2017 By the Numbers : March 22, 2017 Mar 22 2017
Five ESG Stocks Poised For Big Turnarounds Mar 13 2017
Analogic to Launch Breakthrough Checkpoint Security Screening System for European Aviation Market at... Mar 08 2017
Edited Transcript of ALOG earnings conference call or presentation 6-Mar-17 10:00pm GMT Mar 06 2017
Analogic posts 2Q profit Mar 06 2017
Analogic Announces Results for the Second Quarter ended January 31, 2017 and Declares Quarterly... Mar 06 2017
Analogic Announces Timing for Second Quarter 2017 Earnings Conference Call and Webcast Feb 21 2017
ETFs with exposure to Analogic Corp. : January 11, 2017 Jan 11 2017
Analogic Corp. :ALOG-US: Earnings Analysis: Q1, 2017 By the Numbers : December 14, 2016 Dec 14 2016
Analogic Corporation (ALOG): Are Hedge Funds Right About This Stock? Dec 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)